(Q28301344)

English

Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review

scientific article

In more languages

Statements

scholarly article

0 references

1 reference

Europe PubMed Central

Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise review (English)

0 references

1 reference

based on heuristic

inferred from title

3

object named as

Guido Marcucci

0 references

Clara D. Bloomfield

4

object named as

Clara D Bloomfield

0 references

Krzysztof Mrózek

2

object named as

Krzysztof Mrózek

0 references

Claudia D Baldus

1

object named as

Claudia D Baldus

0 references

language of work or name

0 references

publication date

June 2007

0 references

British Journal of Haematology

0 references

137

0 references

387-400

0 references

5

0 references

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.2007.06566.X

20 April 2017

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Risk assessment in patients with acute myeloid leukemia and a normal karyotype

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Nucleophosmin and cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

MLL: a histone methyltransferase disrupted in leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Clinical importance of cytogenetics in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Spectral karyotyping in patients with acute myeloid leukemia and a complex karyotype shows hidden aberrations, including recurrent overrepresentation of 21q, 11q, and 22q.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Cytogenetics in acute leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

ETS transcription factors: possible targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Molecular biology of the Ets family of transcription factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Prognostically useful gene-expression profiles in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06566.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2007.06566.X

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28301344&oldid=1975586139"